Chai Discovery, an A.I. Drug Start-Up, Raises $400 Million
The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to tackle problems like drug discovery.
Record details
Published: 14 July 2026
Source: The New York Times
Category: News
Topics: Healthcare · Finance, VC & PE · Biotech
Retrieved: 14 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
TechCrunch · 15 July 2026
An OpenAI researcher is leaving to build a $2bn AI drug startup that has no name yet
The Next Web AI · 15 July 2026
Investors bet on AI drug discovery despite approval gap
Financial Times Technology (headlines) · 21 July 2026
How AI helps scientists design the next generation of medicines
MIT Technology Review · 23 July 2026
Exclusive: A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public
Retraction Watch · 23 July 2026
STAT+: AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs
STAT News (health AI, headlines) · 29 June 2026
How to cite this record
ethics.ai (14 July 2026), “Chai Discovery, an A.I. Drug Start-Up, Raises $400 Million,” evidence record 1692, https://ethics.ai/record/1692 (originally published by The New York Times).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.